RET

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

RET

RET (REarranged during Transfection) is a transmembrane receptor tyrosine kinase that is activated by a complex made up of a soluble GDNF family ligand (GFL) and a co-receptor that is glycosyl phosphatidylinositol-anchored (GFRalpha).

The enteric nervous system's development depends on RET signaling. The postnatal maintenance of dopaminergic neurons depends on RET, which also controls the development of sympathetic, parasympathetic, motor, and sensory neurons. Additionally, RET functions as a driver oncogene in a number of human cancers. In papillary thyroid, lung, colorectal, pancreatic, and breast cancers, RET has been found to fuse with a number of partner genes. Tyrosine kinase inhibitors (TKIs) for RET, particularly RET-specific inhibitors, show promising results against such cancers.

RET related products

Cat No.	Product Name	CAS No.	Product Description
V3376	AST487 (NVP- AST487)	630124-46-8	AST487 (also known as NVP- AST487) is a novel and potent inhibitor of RET kinase with anticancer activity.
V4663	BBT-594	882405-89-2	BBT-594 (also known as NVP-BBT594) is a novel, potent and selective receptor tyrosine kinase RET inhibitor used for cancer treatment.
V69553	Enbezotinib (enantiomer) (TPX-0046 (enantiomer))	2359650-19-2	Enbezotinib (Enantiomer) (Compound 44) is the enantiomeric form of enbezotinib.
V69549	FHND5071	2761152-16-1	FHND5071 is a potent and specific RET kinase inhibitor.
V3552	GSK3179106	1627856-64-7	GSK3179106 is a novel, potent, selective, and gut-restricted RET kinase inhibitorwith anIC50of 0.4 nM.
V69539	NSC194598	5358-76-9	NSC194598 is a p53 DNA binding inhibitor (antagonist) with IC50s of 180 nM and 2-40 μM for inhibiting p53 sequence-specific DNA binding in vitro and in vivo, respectively.
V4830	Pralsetinib (BLU 667)	2097132-94-8	Pralsetinib (GAVRETO; BLU667; BLU-667) is a novel, highly potent, selective, FDA approved RET inhibitor with anticancer activity.
V69544	Pyrazoloadenine	2380-63-4	Pyrazoloadenine is a potent inhibitor of the RET lung cancer oncoprotein.
V69547	RET-IN-22	2918281-79-3	RET-IN-22 (compound 17b) is a specific, orally bioactive RET inhibitor (antagonist) with IC50s of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively.
V69551	RET-IN-23	2479961-46-9	RET-IN-23 (compound 17) is a potent orally bioactive RET inhibitor (antagonist) with IC50s of 1.32 and 2.50 for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, and RET-M918T respectively.
V69554	RET-IN-24	2583767-68-2	RET-IN-24 (Compound 26) is a selective RET tyrosine kinase inhibitor (TKI) (antagonist) with anti-tumor activity.
V69540	RET-IN-25	2965703-02-8	RET-IN-25 (compound 6b) is a RET kinase inhibitor (antagonist) with anti-cancer activity.
V79251	RET-IN-26		RET-IN-26 (compound D5) is a RET kinase inhibitor (antagonist) with IC50 of 0.33 μM.
V69543	RET-IN-3	2414374-53-9	RET-IN-3 (compound 34) is a selective RETV804M kinase inhibitor (antagonist) with IC50 of 19 nM.
V51535	RET-IN-4	2436473-55-9	RET inhibitor
V69545	RET-IN-5	2725770-20-5	RET-IN-5 is a potent RET inhibitor (antagonist) with IC50 of 4.57 nM (WO2021213476A1, compound 18).
V69550	RET-IN-6	2715208-83-4	RET-IN-6 is a potent RET inhibitor (antagonist) with IC50 of 4.57 nM (CN113461670A, compound 321).
V69546	RET-IN-7	2763386-05-4	RET-IN-7 displays potent RET kinase inhibition in vitro and potent efficacy against RET-driven tumor xenografts in vivo.
V87855	RET/TRKA-IN-1		RET/TRKA-IN-1 (Compound 13) is a dual inhibitor of RET (IC50=0.375 µM) and TRKA. RET/TRKA-IN-1 inhibits the cell viability of LC-2 and KM12 cells with GI50 of 0.72 and 0.25 μM, respectively.
V2168	RETV804M kinase inhibitor	2414909-94-5	RETV804M kinase inhibitor (Compound 13) is a novel and potent inhibitor of RETV804M kinase, which is the anticipated drug-resistant mutant of RET kinase.